<DOC>
	<DOCNO>NCT02385240</DOCNO>
	<brief_summary>To compare safety efficacy Perrigo 's rosacea drug product compare FDA approve rosacea drug product treatment facial erythema rosacea .</brief_summary>
	<brief_title>Comparative Safety Efficacy Two Rosacea Products Treatment Facial Erythema Rosacea</brief_title>
	<detailed_description />
	<mesh_term>Rosacea</mesh_term>
	<mesh_term>Brimonidine Tartrate</mesh_term>
	<criteria>1 . Provide IRB approve write informed consent/assent . 2 . Male nonpregnant female , ≥ 18 year age . 3 . Diagnosis rosacea moderate severe erythema face define : score ≥ 3 Clinician 's Erythema Assessment ( CEA ) score ≥ 3 Patient 's SelfAssessment ( PSA ) Visit 1/Day 1 ( Baseline ) prior first application study medication hour 0 . 4 . Willing able understand comply requirement study . 5 . Be general good health free clinically significant disease , rosacea , might interfere study evaluation . 6 . Females childbearing potential addition negative urine pregnancy test , must willing use acceptable form birth control study 1 . Females pregnant , breast feeding , plan pregnancy within study participation period . 2 . Presence three ( 3 ) facial inflammatory lesion rosacea . 3 . Current diagnosis Raynaud 's syndrome , thromboangiitis obliterans , orthostatic hypotension , severe cardiovascular disease , cerebral coronary insufficiency , renal hepatic impairment , scleroderma , Sjögren 's syndrome depression . 4 . Other facial condition Investigator 's opinion might interfere rosacea diagnosis and/or assessment include limited : acne conglobata , acne fulminans , rhinophyma , facial pustulosis chin , perioral dermatitis , demodicidosis , facial keratosis pilaris , seborrheic dermatitis , acute lupus erythematosus , actinic keratosis , acne , dermatitis , psoriasis , squamous cell carcinoma , eczema , acneiform eruption cause medication , steroid acne , steroid folliculitis , bacterial folliculitis . 5 . Any uncontrolled , chronic serious disease medical condition would prevent participation clinical trial , judgment Investigator , would put subject undue risk might confound study assessment ( plan hospitalization study ) . 6 . Subject consumes excessive alcohol , abuse drug , condition could compromise subject 's ability comply study requirement . 7 . Excessive facial hair ( beard , sideburn , moustache , etc . ) would interfere diagnosis assessment rosacea . 8 . History hypersensitivity allergy ingredient study medication . 9 . Previous enrollment study . 10 . Nonresponders prior treatment topical brimonidine . 11 . Currently use product contain brimonidine tartrate oxymetazoline . 12 . Start change dose hormonal treatment . 13 . Start change dose tricyclic tetracyclic antidepressant , cardio glycoside , beta blocker calcium channel blocker antihypertensive agent 3 month ( 90 day ) prior baseline throughout study . Use therapy must remain constant study . 14 . Current treatment start follow class drug : monoamine oxidase ( MAO ) inhibitor , barbiturate , opiate , sedative , systemic anesthetic alphaagonists , medicine psychosis , medicine hyperactivity 15 . Use within 6 month ( 180 day ) prior baseline study oral retinoids therapeutic vitamin A supplement great 10,000 units/day ( multivitamin allow ) . 16 . Use within 12 week ( 84 day ) prior baseline study systemic immunomodulators 17 . Use medicate makeup throughout study and/or significant change use consumer product within 4 week ( 28 day ) study entry throughout study . 18 . Participation clinical study involve investigational product device 4 week ( 28 day ) prior baseline throughout study . 19 . Use follow topicals face within 14 day prior baseline study antibiotic and/or prescription antiinflammatory agent include ophthalmic 20 . Over counter ( OTC ) topical antiacne medication 7 day prior baseline 21 . Chronic , daily use OTC antiinflammatory medication 7 day ( include lowdose aspirin cardiac prophylaxis ) , 7 day prior baseline throughout study . Subjects may use acetaminophen pain relief , need throughout study . 22 . Use tanning booth , sun lamp , sunbathe , phototherapy excessive ultraviolet ( UV ) exposure sun 7 day prior baseline throughout study . 23 . Use Niacin ≥500 mg per day within 7 day study start throughout study . 24 . Use topical astringent abrasive within 2 day study start throughout study . 25 . Use antipruritic ( include antihistamine ) , spa treatment chlorine exposure ( swim , etc . ) within 24 hour study visit ( Visit 1 Visit 3 ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>